Mumbai: Biocon Biologics Ltd made leadership changes on Friday, revealing the appointments of Rhonda Duffy as Chief Operating Officer (COO) and Sandeep Athalye as Chief Development Officer.
The subsidiary company of Biocon Ltd also introduced David Gibson as the Global Head of Business Development, responsible for overseeing licensing, strategic partnerships, and business development endeavours.
Notably, Gibson joins the company after his tenure at GlaxoSmithKline (GSK).
With her extensive background in the global pharmaceuticals industry spanning over 30 years, Rhonda Duffy will take charge of overseeing manufacturing, quality, and supply chain management, the company explained in a statement.
Athalye, who has held the position of Chief Medical Officer at Biocon Biologics for more than six years, has now been promoted to the role of Chief Development Officer. In this capacity, he will oversee areas including Chemistry, Manufacturing, and Controls (CMC), clinical development, as well as medical and regulatory affairs, the statement further indicated.
These new additions to the leadership team bring rich, global experience which will help prepare the organisation for the future and ensure a seamless integration of the recently acquired global biosimilars business from Viatris, Biocon Biologics CEO Managing Director Shreehas Tambe said.
The company announced the appointment of Stephanie Wasco as the Head of Communications – Advanced Markets. In this role, she will spearhead corporate and marketing communications, as well as product branding efforts in advanced markets such as the United States and Europe.
